Berenyiova, A.; Bernatova, I.; Zemancikova, A.; Drobna, M.; Cebova, M.; Golas, S.; Balis, P.; Liskova, S.; Valaskova, Z.; Krskova, K.;
et al. Vascular Effects of Low-Dose ACE2 Inhibitor MLN-4760—Benefit or Detriment in Essential Hypertension? Biomedicines 2022, 10, 38.
https://doi.org/10.3390/biomedicines10010038
AMA Style
Berenyiova A, Bernatova I, Zemancikova A, Drobna M, Cebova M, Golas S, Balis P, Liskova S, Valaskova Z, Krskova K,
et al. Vascular Effects of Low-Dose ACE2 Inhibitor MLN-4760—Benefit or Detriment in Essential Hypertension? Biomedicines. 2022; 10(1):38.
https://doi.org/10.3390/biomedicines10010038
Chicago/Turabian Style
Berenyiova, Andrea, Iveta Bernatova, Anna Zemancikova, Magdalena Drobna, Martina Cebova, Samuel Golas, Peter Balis, Silvia Liskova, Zuzana Valaskova, Katarina Krskova,
and et al. 2022. "Vascular Effects of Low-Dose ACE2 Inhibitor MLN-4760—Benefit or Detriment in Essential Hypertension?" Biomedicines 10, no. 1: 38.
https://doi.org/10.3390/biomedicines10010038
APA Style
Berenyiova, A., Bernatova, I., Zemancikova, A., Drobna, M., Cebova, M., Golas, S., Balis, P., Liskova, S., Valaskova, Z., Krskova, K., Zorad, S., Dayar, E., & Cacanyiova, S.
(2022). Vascular Effects of Low-Dose ACE2 Inhibitor MLN-4760—Benefit or Detriment in Essential Hypertension? Biomedicines, 10(1), 38.
https://doi.org/10.3390/biomedicines10010038